Drugs News and Research

RSS

Intellikine, Tragara Pharmaceuticals awarded $1M each for developing new multiple myeloma therapies

The Multiple Myeloma Research Foundation (MMRF) today announced that two San Diego area biotech firms, Intellikine and Tragara Pharmaceuticals, Inc. will receive funding via its MMRF Biotech Investment Award program. The MMRF Biotech Investment Awards represent a multi-year research grant commitment to fund the early-stage drug development of novel compounds and approaches that show potential in treating multiple myeloma. Based on the companies' achievement of clearly defined milestones, the MMRF will commit a total of $1,000,000 to each company by the end of 2011.

30 Mar 2010

LCT receives approval for New Zealand Phase II human trial of DIABECELL

Living Cell Technologies Limited, a global company pioneering the development of a cell implant to treat diabetes, today announced that it has received approval to advance to the next phase of its New Zealand Phase II human clinical trial with its groundbreaking DIABECELL®. The approval follows a positive assessment from the New Zealand Data Safety and Monitoring Board of the first four patients to receive its DIABACELL® implants.

30 Mar 2010

Health industry will see more patients with reform; Physicians give mixed reviews

The Atlanta Journal-Constitution: "The health care plan aims to send a wave of paying patients to hospitals, doctors and pharmacists." Expanded coverage will mean less uncompensated care, a boon to traditional safety-net hospitals, but also more Medicaid patients. Hospitals say Medicaid fees don't cover their costs, so that influx could hurt the bottom line.

30 Mar 2010

Industry groups, lobbying firms gain from health overhaul

The Associated Press: Under the new health care law, "pharmaceutical lobbyists won new federal policies they coveted and set a trajectory for long-term industry growth." Ramsey Baghdadi, a Washington health policy analyst, "projects a $30 billion, 10-year net gain for the industry. 'I don't see how they could have done much better,'" he said.

29 Mar 2010

Unrestricted availability of food can trigger overconsumption and obesity

Some of the same brain mechanisms that fuel drug addiction in humans accompany the emergence of compulsive eating behaviors and the development of obesity in animals, according to research funded by the National Institute on Drug Abuse (NIDA), a component of the National Institutes of Health.

29 Mar 2010

Today's OpEds: The states' lawsuits, the need to trim health costs and industry winners

No sooner had President Obama signed comprehensive health care reform than the attorneys general of 14 states scurried to the federal courts to challenge the law. ... [they] are doing a disservice to their constituents by opposing Medicaid expansion and a mandate that everyone buy insurance, with subsidies for low- and middle-income people (3/28).

29 Mar 2010

Generex Biotechnology announces FDA Expanded Access Treatment IND Program for Generex Oral-lyn

Generex Biotechnology Corporation, the leader in drug delivery for metabolic diseases through the inner lining of the mouth, today announced that it has expanded its plans for its United States Food and Drug Administration (FDA) Expanded Access Treatment IND Program for its flagship product, Generex Oral-lyn™, to include licensed and qualified Nurse Practitioners in the United States.

29 Mar 2010

Chakra Biotech completes MYR18.2m Series B investment round

Chakra Biotech Sdn Bhd, a Malaysian based Contract Research Organization, has completed a MYR18.2m Series B funding round. This brings total funding for the company to MYR20.0m. Malaysian Life Sciences Capital Fund Ltd. (MLSCF) and the Malaysian Technology Development Corporation Sdn Bhd (MTDC) participated in the round.

29 Mar 2010

Ligand Pharmaceuticals' LGD-4033 SARM Phase I study data featured at 14th endocrinology congress

Ligand Pharmaceuticals Incorporated today announced that data from a Phase I study with its selective androgen receptor modulator (SARM) LGD-4033 was featured today in a poster presentation at the 14th International Congress of Endocrinology in Kyoto, Japan. This Phase I clinical trial was the first study in humans of LGD-4033, and evaluated the safety, tolerability and pharmacokinetic profiles of the molecule in a single escalating dose, double blind, placebo-controlled study in 48 healthy volunteers.

29 Mar 2010

Positive results from Pearl Therapeutics' Phase 1 study of inhaled combination bronchodilator for COPD

Pearl Therapeutics Inc., a company developing clinically differentiated combination therapies for the treatment of highly prevalent chronic respiratory diseases, today announced positive results from a Phase 1 safety and pharmacokinetics study of PT003, its lead combination therapeutic for the treatment of chronic obstructive pulmonary disease (COPD). Based on these results, and previously announced positive results from Phase 2a studies of PT003's individual components, the company has advanced PT003 into a Phase 2b trial.

29 Mar 2010

Parenteral Biotech to supply and distribute Sinovac Biotech's Anflu and PANFLU.1 vaccines in India

Sinovac Biotech Ltd., a leading China-based vaccine manufacturer, announced today it has entered into exclusive license, supply and distribution agreements with Parenteral Biotech Ltd., a subsidiary of Parenteral Drugs (India), Ltd., an India-based pharmaceutical company. Pursuant to the agreements, Parenteral is authorized to register, supply and distribute Sinovac's Anflu (seasonal influenza vaccine) and PANFLU.1 (H1N1 vaccine) to the government of India and private market in India. Currently, the registration process is ongoing in India.

29 Mar 2010

Upgrading to policy with no limits benefits insurance agent

It can be instructive to consider not just what long term care insurance professionals recommend, but what they do -- for their own personal protection. A good example is the case of Kim Galatolo, an agent with LTC Financial Partners LLC one of the nation's most experienced long term care insurance agencies. In California, where Galatolo lives and works, the firm is known as LTC Partners & Insurance Services, LLC.

29 Mar 2010

PROCAPS granted exclusive rights to commercialize Pro-Pharmaceuticals' DAVANAT in Colombia

Pro-Pharmaceuticals, Inc., a developer of therapeutics that target Galectin receptors to treat cancer and fibrosis, today announced that it has granted PROCAPS S.A. exclusive rights to market and sell DAVANAT® to treat cancer in Colombia, South America. Phase ll clinical trial results for late-stage colorectal cancer patients demonstrate that when DAVANAT® is co-administered with the chemotherapy drug 5-FU, survival increased by 46% over the best standard of care and reduced serious adverse events associated with chemotherapy.

29 Mar 2010

Gateway Foundation Alcohol and Drug Rehab's effective substance abuse treatment recognised

Chicago alderman, elected state officials, local law enforcement representatives and West Side community activists were among those touring the Gateway Foundation's Alcohol and Drug Rehab's Westside Treatment Center on March 20.

29 Mar 2010

Seniors with diabetes and dementia more likely to fall into Medicare Part D prescription drug plan

Among seniors, women and patients with diabetes and dementia are the most likely to fall into the Medicare Part D prescription drug plan "donut hole" - the gap occurring after beneficiaries reach their annual coverage limit and before catastrophic coverage kicks in - according to new research published online in the Journal of General Internal Medicine.

29 Mar 2010

Addiction to high calorie fat rich food: likened to cocaine and heroin addiction

In a new research our worst fears are confirmed – fatty, fried and fattening foods are addictive. The addiction with these delicious ‘yummies’ may be as potent as that with cocaine or heroin. The study was conducted on experimental animals, rats in this case. When fed with fatty foods in great quantities these rats showed a compulsive need to eat.

29 Mar 2010

New data on EHT 0202 for treatment of patients with AD presented at Geneva/Springfield Symposium

ExonHit Therapeutics announced today that promising new data on EHT 0202, its lead candidate in Alzheimer's disease, were presented at the 11th International Geneva/Springfield Symposium on Advances in Alzheimer Therapy from March 24th to March 27th in Geneva, Switzerland.

29 Mar 2010

Two-drug combination destroys precancerous colon polyps

A two-drug combination destroys precancerous colon polyps with no effect on normal tissue, opening a new potential avenue for chemoprevention of colon cancer, a team of scientists at The University of Texas M. D. Anderson Cancer Center reports in the advance online edition of the journal Nature.

29 Mar 2010

Diagnostic test for alcohol consumption: Measuring protein changes in blood

Measuring a set of protein changes in the blood linked to alcohol use may potentially lead to a more accurate diagnostic test than those currently available, according to Penn State College of Medicine researchers.

29 Mar 2010

Study provides new clues to obesity epidemic

In a newly published study, scientists from The Scripps Research Institute have shown for the first time that the same molecular mechanisms that drive people into drug addiction are behind the compulsion to overeat, pushing people into obesity.

29 Mar 2010

Drugs News and Research

Intellikine, Tragara Pharmaceuticals awarded $1M each for developing new multiple myeloma therapies

LCT receives approval for New Zealand Phase II human trial of DIABECELL

Health industry will see more patients with reform; Physicians give mixed reviews

Industry groups, lobbying firms gain from health overhaul

Unrestricted availability of food can trigger overconsumption and obesity

Today's OpEds: The states' lawsuits, the need to trim health costs and industry winners

Generex Biotechnology announces FDA Expanded Access Treatment IND Program for Generex Oral-lyn

Chakra Biotech completes MYR18.2m Series B investment round

Ligand Pharmaceuticals' LGD-4033 SARM Phase I study data featured at 14th endocrinology congress

Positive results from Pearl Therapeutics' Phase 1 study of inhaled combination bronchodilator for COPD

Parenteral Biotech to supply and distribute Sinovac Biotech's Anflu and PANFLU.1 vaccines in India

Upgrading to policy with no limits benefits insurance agent

PROCAPS granted exclusive rights to commercialize Pro-Pharmaceuticals' DAVANAT in Colombia

Gateway Foundation Alcohol and Drug Rehab's effective substance abuse treatment recognised

Seniors with diabetes and dementia more likely to fall into Medicare Part D prescription drug plan

Addiction to high calorie fat rich food: likened to cocaine and heroin addiction

New data on EHT 0202 for treatment of patients with AD presented at Geneva/Springfield Symposium

Two-drug combination destroys precancerous colon polyps

Diagnostic test for alcohol consumption: Measuring protein changes in blood

Study provides new clues to obesity epidemic

Drug Discovery - Second Edition eBook

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News